Pradaxa
intended to alleviate the risk of stroke and systemic embolism in atrial fibrillation.
Strengths: 150mg
Where to Check Availability
Medicine details
- Therapeutic class
Direct Thrombin Inhibitor
- Pharmacological class
Direct Oral Anticoagulant (DOAC)
- Minor side effects
dyspepsia; abdominal pain; nausea
- Moderate side effects
anaemia; gastritis
- Dosage forms
Capsule, hard
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Boehringer Ingelheim
- Onset Time
1–2 hours
- Duration
12–24 hours
- Storage instructions
Store in original bottle; keep tightly closed and away from moisture.
- Drug interactions
rifampicin; verapamil; amiodarone
- Age restrictions
Not for use in children.
Contraindications
hypersensitivity to dabigatran; severe renal impairment; active bleeding; mechanical prosthetic heart valve
Precautions and warnings
risk of haemorrhage, monitor for bleeding; use caution in patients with history of gastrointestinal disease; do not chew or open capsules
Serious side effects
major haemorrhage — requires immediate medical attention; gastrointestinal bleeding — requires immediate medical attention; anaphylaxis — requires immediate medical attention
Patient summary
intended to alleviate the risk of stroke and systemic embolism in atrial fibrillation.
Mechanism of action
It acts as a potent, competitive, direct thrombin inhibitor. By blocking thrombin, it prevents the conversion of fibrinogen to fibrin, thereby inhibiting clot formation in the bloodstream.
Pregnancy and breastfeeding
Pregnancy: Not recommended. Breastfeeding: Breastfeeding should be stopped during treatment.
Pradaxa
intended to alleviate the risk of stroke and systemic embolism in atrial fibrillation.
Editorial Notes
- Active ingredient(s): Dabigatran
- Listed indication(s): Atrial Fibrillation, Venous Thromboembolism
Available option
- 20 capsules - 150 mg1467-150-mg-17680